Earnings per share for the last twelve months: Tempest Therapeutics Inc (TPST)
Tempest Therapeutics research center resources are fully deployed in the development of anti-tumor agents. The company's TTM net income per share reflects the dynamics of these expenditures, where the -4.48 level serves as a critical benchmark. However, a high dependency on the outcome of liver cancer treatment trials and the risk of rapid capital depletion create significant instability for the business.
Analytical breakdowns and data insights for company Tempest Therapeutics Inc (TPST)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Tempest Therapeutics|TPST - Long-Term Liabilities to Capital|Short-Term Debt to Equity Tempest Tx|TPST - Company Total Debt|Debt to Book Capitalization Ratio Tempest Therapeutics, Inc.|TPST - Long-Term Liabilities|Company Short-Term Debts Tempest Therapeutics|Quick Liquidity tempesttx.com
- net income and valuation multiples indicators:
TPST - Net Financial Result|Future Profit Tempest Therapeutics|TPST - Market Price to Net Income Ratio|Projected Price to Earnings Tempest Therapeutics, Inc.|TPST - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Tempest Therapeutics, Inc.|TPST - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Tempest Therapeutics|TPST - Earnings per share for the trailing year|Quarterly EPS earnings growth tempesttx.com|TPST - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Tempest Therapeutics
Initial company analysis:TPST - Tempest Therapeutics
Investors seek a balance between asset value and business quality. This metric reflects the aggregate net income per share over the last four quarters, combining data from 10-K and 10-Q filings. For the biotech company Tempest Therapeutics (TPST), which develops selective PPAR inhibitors, this indicator demonstrates the efficiency of R&D expenditures. The net income per share trend over the last four quarters allows for the timely identification of a fundamental reversal.
Key competitors
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share for the last 12 months BCAX (Bicara Therapeutics Inc.)|Earnings per share for the last four quarters PSNL|Net earnings per share (EPS TTM) ERAS (Erasca)|Delcath Systems Inc (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Aura Corp (AURA) - Net earnings per share for the last 12 months|candeltx.com (CADL) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months ARAY (accuray.com)|SLS (SELLAS Life Sciences Group, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Actuate Therapeutics Inc. ACTU|Earnings per share for the last twelve months Citius Oncology, Inc (CTOR)|Net earnings per share for the last four quarters tuhurabio.com|Protara Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters FATE (fatetherapeutics.com)|WHWK: Net earnings per share for the last 12 months|Earnings per share for the trailing year TCRX (TScan Therapeutics)|CSBR (championsoncology.com) - Net earnings per share for the last 12 months|XBIT: Earnings per share for the last four quarters|CVM (CEL-SCI Corp.) - Net earnings per share (EPS TTM)|OSTX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RADX|ARTV - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Adlai Nortye ANL|Earnings per share for the trailing year VERU|Xilio - Net earnings per share (EPS TTM)|RENB - Net earnings per share (EPS TTM)|muraloncology.com (MURA) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months KAPA (Kairos Pharma)|OKUR (OnKure Therapeutics, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CytoMed GDTC|Net earnings per share for the last 12 months CRIS (Curis, Inc.)|Net earnings per share (EPS TTM) apollomicsinc.com (APLM)|Tharimmune - Net earnings per share for the last 12 months|Earnings per share for the last four quarters ADVB (Advanced Biomed Inc.)|Genprex, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Calidi Biotherapeutics CLDI|SBFM: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Xenetic Biosciences, Inc.|Earnings per share for the last twelve months Salarius Pharmaceuticals, Inc.|Purple Biotech Ltd (PPBT) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months AONC (American Oncology Network)|Earnings per share for the last four quarters BGNE|Earnings per share for the last twelve months Checkpoint Therapeutics CKPT|ELEV (elevationoncology.com) - Earnings per one share for the last 12 months|ICAD - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Ikena Oncology, Inc. IKNA|NTBL (Notable Labs Inc.) - Net earnings per share for the last 12 months|VIRX: Earnings per share for the last four quarters|MOR (MorphoSys AG) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months nayabiosciences.com (NAYA)|Net earnings per share (EPS TTM) AAPGV
